OSI-906 (Linsitinib)

OSI-906 (Linsitinib)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。

価格 在庫  
USD 214 あり
USD 239 あり
USD 340 あり
USD 907 あり

OSI-906 (Linsitinib) 化学構造
分子量: 421.49

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare IGF-1R Inhibitors
    IGF-1R製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 OSI-906 (Linsitinib)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。
ターゲット IGF-1R InsR
IC50 35 nM 75 nM [1]
In vitro試験 OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-Fuk M1fGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEK4NFYh|ryP NWrSfZZOW0GQR1XS
KS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe3NYVKSzVyPUCuNFM5OzVizszN M2rmV3NCVkeHUh?=
TE-11 M3SxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfkbYdKSzVyPUCuNFc5OjJizszN M3vxfnNCVkeHUh?=
EW-1 NGLMXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnKfpE5UUN3ME2wMlA5PTh3IN88US=> MVrTRW5ITVJ?
HMV-II NUXlfGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHtTWM2OD1yLkC4PFQ3KM7:TR?= M3HU[XNCVkeHUh?=
COLO-205 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PoSWlEPTB;MD6xNFQ2PCEQvF2= NGfhdJJUSU6JRWK=
ES1 NYH6cYdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTRTWM2OD1yLkGwOlk3KM7:TR?= NE\hXoNUSU6JRWK=
GDM-1 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUO2O|Ih|ryP Mlz3V2FPT0WU
ML-2 NEi0NGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUW4PVYh|ryP MnP4V2FPT0WU
Saos-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMU[1NlYh|ryP NH\tVWJUSU6JRWK=
NCI-H1355 M1Xadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH3TWM2OD1yLkG4NVM2KM7:TR?= M4DMSnNCVkeHUh?=
G-401 NE\tfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP0cZJKSzVyPUCuNVgzOyEQvF2= M1\5UXNCVkeHUh?=
EW-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PhTWlEPTB;MD6xPFc4PyEQvF2= NVzlOGF4W0GQR1XS
EW-7 NFrBdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMUi4PFEh|ryP NHXw[VVUSU6JRWK=
NCI-H727 NH3Kd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPqbWhKSzVyPUCuNVk4QTRizszN MXjTRW5ITVJ?
LCLC-97TM1 M2OzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMkC5OVUh|ryP MVTTRW5ITVJ?
NCI-H650 NUfKVGhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7xT3VTUUN3ME2wMlIyOzh2IN88US=> NHr4RXZUSU6JRWK=
NCI-H2122 M1jXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC0TWM2OD1yLkKzNlk6KM7:TR?= NVXQZ4JqW0GQR1XS
SK-N-DZ NGXoTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfxW3lkUUN3ME2wMlI{Pjl6IN88US=> NG\NZ5BUSU6JRWK=
HT-29 NGfmeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX0SFNLUUN3ME2wMlI1OjR6IN88US=> NXXQTo9nW0GQR1XS
LB771-HNC M4T0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMkW5NVUh|ryP NUnaSo5QW0GQR1XS
HT-144 M3TuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\l[FBKSzVyPUCuNlYyQTFizszN Ml[zV2FPT0WU
LAN-6 NYLXcoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLyTWM2OD1yLkK2N|Q5KM7:TR?= MWDTRW5ITVJ?
EW-18 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMkewNFEh|ryP NFiyNpFUSU6JRWK=
LS-1034 NH7HWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrh[Ip6UUN3ME2wMlI4OTN{IN88US=> NYnxZnJ3W0GQR1XS
EW-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMki0N|Ih|ryP NXjoUmlvW0GQR1XS
SNU-C1 NEPoe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfH[Fg6UUN3ME2wMlI6OzF|IN88US=> NGfGSZhUSU6JRWK=
RS4-11 M17k[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTPTWM2OD1yLkOzO|U5KM7:TR?= NVv6d2p7W0GQR1XS
ES4 NV64TXI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfpTWM2OD1yLkSxNFM5KM7:TR?= MmXVV2FPT0WU
COLO-320-HSR NIHER2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNEGzOlgh|ryP NWf1S2RbW0GQR1XS
NB10 NHPyOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwNEW0N|ch|ryP Mon4V2FPT0WU
BFTC-905 M2Twc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX36fWYyUUN3ME2wMlQ3PzV6IN88US=> MYDTRW5ITVJ?
A375 NGnveopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNEe2NVch|ryP MmXXV2FPT0WU
SJRH30 NFW4SWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInmXpJKSzVyPUCuOVA5OjJizszN NVzSRZJmW0GQR1XS
NOS-1 M13Ge2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XOnl{UUN3ME2wMlUzOjZ5IN88US=> NUTYcnJ3W0GQR1XS
SIG-M5 NEPhV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNUO1OVch|ryP MWTTRW5ITVJ?
DOK M{Tzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3YTWM2OD1yLkW1OkDPxE1? MV7TRW5ITVJ?
NB69 NFnVTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwNUiyOVch|ryP NV\3c41CW0GQR1XS
SK-NEP-1 M3OxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWntN406UUN3ME2wMlYxOjN4IN88US=> MU\TRW5ITVJ?
SK-MM-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS2TWM2OD1yLk[1OFkyKM7:TR?= NFu0c5lUSU6JRWK=
NCI-H358 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNkewPFIh|ryP MWjTRW5ITVJ?
RH-1 NXfBRmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LTb2lEPTB;MD63OFg2QSEQvF2= MX3TRW5ITVJ?
NH-12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ThOGlEPTB;MD63OlA1PiEQvF2= MmjiV2FPT0WU
TE-12 M4K4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XQSmlEPTB;MD63OlQ5PiEQvF2= NHjyS4JUSU6JRWK=
COLO-668 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvZXmYzUUN3ME2wMlg1PjZ4IN88US=> MWfTRW5ITVJ?
PANC-08-13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;uZ2lEPTB;MD64OlM4PyEQvF2= MonyV2FPT0WU
HCC2998 NGDydpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm3d5E2UUN3ME2wMlg5OjZ|IN88US=> M3rJenNCVkeHUh?=
ABC-1 M3TldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC1dldKSzVyPUCuPVA{PTJizszN MVXTRW5ITVJ?
ES6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4bGlEPTB;MD65NVA3PiEQvF2= MYLTRW5ITVJ?
SNU-387 NULqRpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXlSo1KSzVyPUCuPVk{QTNizszN Mmf1V2FPT0WU
CMK MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Tl[mlEPTB;MD65PVkzQSEQvF2= MWPTRW5ITVJ?
SJSA-1 NETEPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzCTWM2OD1zLkCzOlU{KM7:TR?= NWfDOms3W0GQR1XS
SIMA MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwME[4NlUh|ryP MWnTRW5ITVJ?
ES3 M1HJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj5fY5KSzVyPUGuNVIzQTdizszN MXnTRW5ITVJ?
IGROV-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvTTWM2OD1zLkG1OFQ1KM7:TR?= MWLTRW5ITVJ?
MEL-JUSO NV\5d2syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwMUW3OVkh|ryP MmniV2FPT0WU
T84 NIjQdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLoWXJKSzVyPUGuNlA6OTRizszN MUPTRW5ITVJ?
CAL-85-1 NV[4fVg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv2TWM2OD1zLkKzNVM5KM7:TR?= NFfrU2FUSU6JRWK=
RD M1vnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzRbFBKSzVyPUGuNlY1PTVizszN MmTPV2FPT0WU
TE-8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLKTWM2OD1zLkOxOFYzKM7:TR?= MVrTRW5ITVJ?
L-363 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[0UmlEPTB;MT6zOFIxQCEQvF2= MX;TRW5ITVJ?
EKVX M3XIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nr[mlEPTB;MT6zOFU3QCEQvF2= NYjRZlA2W0GQR1XS
SK-MEL-3 M37R[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq0T3pKSzVyPUGuOFg2PTZizszN MUTTRW5ITVJ?
TGBC24TKB NF3oT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi1cndKSzVyPUGuOVAyQTNizszN NHzmcYVUSU6JRWK=
NCI-H1770 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwNUGxNVMh|ryP Ml3XV2FPT0WU
HuH-7 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76TJZ1UUN3ME2xMlYxODl6IN88US=> MWPTRW5ITVJ?
HL-60 M1G5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXSR2xKUUN3ME2xMlY3QTJ6IN88US=> NXKyb5d4W0GQR1XS
TE-1 M4Tqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfOTWM2OD1zLkewPVQ2KM7:TR?= MYXTRW5ITVJ?
LC-2-ad NXPI[GFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi4eXc6UUN3ME2xMlc{QDh5IN88US=> MUHTRW5ITVJ?
LB647-SCLC NVzCNJRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwN{[1PFMh|ryP M1XDSnNCVkeHUh?=
NCI-H2171 NIm3bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ESppTUUN3ME2xMlc4PzF4IN88US=> NIT5UlZUSU6JRWK=
SK-PN-DW NWf6Z4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwOUGyPVgh|ryP NFXuempUSU6JRWK=
MC-IXC NFXkPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPjXnA4UUN3ME2xMlk5QThizszN MoHCV2FPT0WU
LS-513 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHflUYdKSzVyPUKuNFU{ODVizszN MnPFV2FPT0WU
EW-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjZcJZKSzVyPUKuNFk5PDRizszN NVW0U5dzW0GQR1XS
OPM-2 NYHIUZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe3WpFEUUN3ME2yMlExOiEQvF2= M3nLe3NCVkeHUh?=
LP-1 NGLzT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\PRolKSzVyPUKuNlU5ODdizszN M1OyTHNCVkeHUh?=
LU-134-A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK5UIdKSzVyPUKuNlc4KM7:TR?= NFnTVYhUSU6JRWK=
CP66-MEL M4jKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG5bYlKSzVyPUKuNlkxOTRizszN NEnme4NUSU6JRWK=
HCC1143 NHLQO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzPXHhKSzVyPUKuOFU{PjhizszN NWm5WmwxW0GQR1XS
LOXIMVI MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy0ZnZvUUN3ME2yMlYxOjFizszN M4m2UnNCVkeHUh?=
TE-10 M4DIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnKTGdHUUN3ME2yMlcxQDN6IN88US=> NGfUNmFUSU6JRWK=
NCI-H1882 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTKTWM2OD1{Lke1NlI4KM7:TR?= M2jBOXNCVkeHUh?=
CHP-126 NH3oO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJwN{[zNVch|ryP MlLxV2FPT0WU
NCI-H1623 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HwZWlEPTB;Mj65NlAzPCEQvF2= NWT0TnljW0GQR1XS
GB-1 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly3TWM2OD1{LkmzOFA1KM7:TR?= M17iOnNCVkeHUh?=
RCC10RGB NUHNV5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPzXmZKSzVyPUKuPVUzQDFizszN NH;G[VdUSU6JRWK=
NCI-H2141 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHkOndKSzVyPUKuPVY5QTZizszN MnnaV2FPT0WU
GI-ME-N MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD1|LkCwOVY2KM7:TR?= NXnoOJF6W0GQR1XS
NCI-H526 NFTKfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:5[2lEPTB;Mz6wOFA5PSEQvF2= NXLON|hLW0GQR1XS
NCI-H747 NYrlUFZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vLbWlEPTB;Mz6wOFk6OiEQvF2= MYnTRW5ITVJ?
SNU-423 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\Xd4ZKSzVyPUOuNlA{OTNizszN NE\3UFJUSU6JRWK=
A427 NVnldFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNwMkW2PVkh|ryP MlLQV2FPT0WU
CAL-12T MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3JTWM2OD1|LkSwO|E{KM7:TR?= MkPZV2FPT0WU
LU-99A NXTrTFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfwTWM2OD1|LkS3NVA2KM7:TR?= NYPS[m93W0GQR1XS
MS-1 NEjFNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTNwNUO0Nlkh|ryP Ml;sV2FPT0WU
SK-LU-1 NGjUO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD1|Lke2Nlk2KM7:TR?= MYXTRW5ITVJ?
SW837 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDEdI5jUUN3ME2zMlc3OzN|IN88US=> NFzpWpNUSU6JRWK=
ES8 M{e4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrZVoxiUUN3ME2zMlg{QDd5IN88US=> NFPjNpdUSU6JRWK=
MZ2-MEL MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P5eGlEPTB;Mz65NlA5PiEQvF2= MUXTRW5ITVJ?
TGW NIrrWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3r[pRKSzVyPUSuNFE{OTFizszN Mn7aV2FPT0WU
GP5d MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zhVGlEPTB;ND6wOVM3OiEQvF2= MV3TRW5ITVJ?
BB49-HNC NHjZR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPNTWM2OD12LkG1NlE{KM7:TR?= NWH2SJhPW0GQR1XS
NB13 NIjnUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDXdotRUUN3ME20MlI3QDh5IN88US=> NInWR|BUSU6JRWK=
NTERA-S-cl-D1 NVSzOVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwMki2NVUh|ryP NYDMfoN5W0GQR1XS
NCI-H1648 NHHBcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnnTlFKSzVyPUSuNlk5OTlizszN MWrTRW5ITVJ?
LCLC-103H NGDlTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXGb3NKSzVyPUSuN|IyQTVizszN MoT4V2FPT0WU
LS-411N MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;rWmlEPTB;ND60OFg5PSEQvF2= M3vIPXNCVkeHUh?=
NCI-H1092 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG5[oZKSzVyPUSuOFU3QDdizszN NVTkTWtRW0GQR1XS
PANC-10-05 NFXoXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPOTWM2OD12Lk[5PFQh|ryP NUjHZmZuW0GQR1XS
DK-MG NU\Wb|RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG5[llRUUN3ME20MlgxQTN|IN88US=> MV3TRW5ITVJ?
OVCAR-5 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\Ve5kyUUN3ME20MlgyOjJ4IN88US=> MYnTRW5ITVJ?
CAL-39 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;YTWM2OD12Lki3Olch|ryP MWHTRW5ITVJ?
TE-441-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi4U|JkUUN3ME20MlkxPTN5IN88US=> MlvlV2FPT0WU
MOLT-16 NILQSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLmRVBKSzVyPUSuPVUzPTNizszN MVzTRW5ITVJ?
MCF7 M3q5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTOVJNQUUN3ME21MlE1PTF5IN88US=> NHTmPWxUSU6JRWK=
CAPAN-1 M1XLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrXdFhxUUN3ME21MlI2PzB5IN88US=> M{DlUHNCVkeHUh?=
PSN1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe0c49yUUN3ME21MlI4OjN3IN88US=> NVX1cok5W0GQR1XS
NCI-H292 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nYc2lEPTB;NT6zNFA1PCEQvF2= Ml:4V2FPT0WU
CPC-N MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vU4tXUUN3ME21MlM6PDF7IN88US=> NH\hN3pUSU6JRWK=
DoTc2-4510 NF32[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\ZUG5bUUN3ME21MlQ2OzdzIN88US=> MVLTRW5ITVJ?
LB1047-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC0dJJKSzVyPUWuOVU6OzNizszN M125eHNCVkeHUh?=
MHH-ES-1 NWfRdo9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP3c3V{UUN3ME21MlU6QTB5IN88US=> NX3lUlVuW0GQR1XS
NMC-G1 M2D3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXhW5BKSzVyPUWuO|AzOjdizszN MljYV2FPT0WU
SW1710 NGHadFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrhV5pmUUN3ME21Mlc1PzVzIN88US=> MWjTRW5ITVJ?
YAPC NFHQVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHqXWlKSzVyPUWuO|YzODFizszN M3PifnNCVkeHUh?=
22RV1 NUTxbow{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPuZ2JKSzVyPUWuPFAxOTlizszN NUexNm01W0GQR1XS
COLO-679 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3meYVKSzVyPUWuPFg6PDhizszN MkixV2FPT0WU
TCCSUP MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nGTWlEPTB;NT65N|I2QSEQvF2= MmLMV2FPT0WU
C2BBe1 M{TOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwOUO5O{DPxE1? NHq5N5lUSU6JRWK=
TE-15 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLwR5hYUUN3ME22MlA3PjB3IN88US=> M37UOXNCVkeHUh?=
SCLC-21H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTZwMUC4OFMh|ryP MVTTRW5ITVJ?
EoL-1-cell NX3ReFZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTZwMU[1OlMh|ryP M2\sd3NCVkeHUh?=
NKM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZwMU[3NUDPxE1? NU\QWnV{W0GQR1XS
NCI-H1304 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjW[ZR5UUN3ME22MlI4PDJ6IN88US=> NWTaT5hPW0GQR1XS
NB6 NXnGbnJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm4TWM2OD14LkK5OlIzKM7:TR?= MmfEV2FPT0WU
NALM-6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK4PJFKSzVyPU[uN|MzOyEQvF2= M1WxTXNCVkeHUh?=
NCI-H522 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnWNY9KSzVyPU[uN|M{ODZizszN NGHQWZRUSU6JRWK=
MV-4-11 NG[5XGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwM{ewO|kh|ryP NVHMeFBkW0GQR1XS
LB2241-RCC NYfZWWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXzcFhKSzVyPU[uN|g3PjdizszN Mme2V2FPT0WU
NCI-H1417 NH\FfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLKTWM2OD14LkSwPFQ4KM7:TR?= NWXNeppDW0GQR1XS
HT-1197 M1fsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\JPWlEPTB;Nj61O|EzOiEQvF2= M1W0NXNCVkeHUh?=
P30-OHK MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y3O2lEPTB;Nj62Nlc4KM7:TR?= NF;BWFFUSU6JRWK=
ALL-PO NXXJPVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTZwN{G5NVYh|ryP M{PSeHNCVkeHUh?=
OVCAR-4 M1PST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZwN{W0NFUh|ryP M3zsUXNCVkeHUh?=
HCC2157 NFLtVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzrTWM2OD14Lke3OFc2KM7:TR?= MYXTRW5ITVJ?
NCI-H838 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljOTWM2OD14Lkm2OFkh|ryP M1f5cHNCVkeHUh?=
NCI-H1299 NVjnbW45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LrfGlEPTB;Nj65O|A6KM7:TR?= MXzTRW5ITVJ?
SW954 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLxTWM2OD15LkKwNFY5KM7:TR?= Ml7MV2FPT0WU
NCI-H441 NWXuUXlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nTWmlEPTB;Nz6zOFA3PSEQvF2= M2njW3NCVkeHUh?=
SK-MEL-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfieY5NUUN3ME23MlQ5Ozd|IN88US=> M{\WTHNCVkeHUh?=
KARPAS-45 M3eyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\FTWM2OD15Lk[1PVI6KM7:TR?= Mne3V2FPT0WU
CAL-54 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe0flU6UUN3ME23MlgzQTd5IN88US=> M1TpPXNCVkeHUh?=
KYSE-180 NUjwXWUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTdwOEi5OFEh|ryP MV;TRW5ITVJ?
NCI-H187 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfkOmwyUUN3ME23Mlk2QTR5IN88US=> NUX1ToN[W0GQR1XS
RT-112 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH0TWM2OD16LkC5Olc4KM7:TR?= M1LIe3NCVkeHUh?=
NCI-H1437 M3;YRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK1dnR7UUN3ME24MlA6Pzl3IN88US=> M17USXNCVkeHUh?=
SNU-449 M{jGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jvSWlEPTB;OD6yPFI4OiEQvF2= NGDG[HFUSU6JRWK=
HCC1187 NGXwZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7NZphKSzVyPUiuNlk{QTFizszN MV\TRW5ITVJ?
NCI-H2030 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj0TWM2OD16LkO3O|E1KM7:TR?= MmXEV2FPT0WU
HuO-3N1 NH7YXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[2TWM2OD16LkO3PFQ1KM7:TR?= M{XLPXNCVkeHUh?=
COLO-792 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\0TJZKSzVyPUiuOFE2OjdizszN NEXJNmNUSU6JRWK=
MIA-PaCa-2 NH7jRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4flW2lEPTB;OD64OVUxQCEQvF2= M4K1RnNCVkeHUh?=
SK-N-FI MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrHTWM2OD17LkC0NlUh|ryP NGnXN5ZUSU6JRWK=
MMAC-SF NHPBemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTlwMEm3OVEh|ryP M3;Ue3NCVkeHUh?=
NCI-H28 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfUS2Q{UUN3ME25MlExPDZ7IN88US=> MY\TRW5ITVJ?
ETK-1 NWjDdGo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO3bIlKSzVyPUmuNlk6PzRizszN MXnTRW5ITVJ?
NCI-H1993 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\6TWM2OD17LkS0NlYyKM7:TR?= MWfTRW5ITVJ?
no-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Ph[WlEPTB;OT60O|EzKM7:TR?= NFfGUYRUSU6JRWK=
ChaGo-K-1 NIqySm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Li[mlEPTB;OT61NVU5OyEQvF2= MoO0V2FPT0WU
NCCIT NVv5[G85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H2UmlEPTB;OT61N|E3QSEQvF2= MlTHV2FPT0WU
SAS NWXGWY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWyWmY1UUN3ME2xNE4zPDhizszN MkG0V2FPT0WU
A673 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvOfYp[UUN3ME2xNE4{PzB2IN88US=> MlziV2FPT0WU
NCI-H1522 NXr0Z5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[3OWlEPTB;MUCuN|cxPyEQvF2= NX7QS5NGW0GQR1XS
NCI-H810 NUP4eIp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjxNHBKSzVyPUGwMlM6ODdizszN M1XWSnNCVkeHUh?=
IST-MES1 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;s[2luUUN3ME2xNE41PTZ2IN88US=> M4qzb3NCVkeHUh?=
GR-ST NVzWTJBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFyLkWwNlQh|ryP NFXJe3pUSU6JRWK=
SUP-T1 M3;5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X2bGlEPTB;MUCuO|MyPyEQvF2= NFj2UW5USU6JRWK=
NB5 NUTiU2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPBWpdyUUN3ME2xNE46ODJ{IN88US=> MX;TRW5ITVJ?
MZ1-PC M1uwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFyLkm1O|Eh|ryP Mk\oV2FPT0WU
SK-CO-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i1NGlEPTB;MUCuPVk{OSEQvF2= MoG3V2FPT0WU
Capan-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFzLkOxPVgh|ryP NGezSFBUSU6JRWK=
697 M2mxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\KTWlEPTB;MUGuOlc2PyEQvF2= NILzVJVUSU6JRWK=
REH NUXjfoxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[w[GlEPTB;MUGuO|Q2OSEQvF2= MlnEV2FPT0WU
GI-1 NXPsT3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFzLki2NVUh|ryP MkC3V2FPT0WU
BB65-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF{LkC5NVYh|ryP M4P6TXNCVkeHUh?=
NCI-H1651 M4ThO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknsTWM2OD1zMj6yOFc5KM7:TR?= MkHjV2FPT0WU
NCI-H1618 M{CwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPZclZKSzVyPUGyMlM6PzZizszN NXWyb4VPW0GQR1XS
NCI-H2081 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\nb2lEPTB;MUKuOlE1OSEQvF2= MnLlV2FPT0WU
GCIY MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3QTWM2OD1zMj63NlE{KM7:TR?= NIDRT5NUSU6JRWK=
NY NH\yUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF|LkC2OFMh|ryP NUXMcnFMW0GQR1XS
PANC-03-27 M2[1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL0TWM2OD1zMz6wPFA4KM7:TR?= NHTuOGtUSU6JRWK=
BHY NIi2V|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF|LkKxNlEh|ryP M3u2XXNCVkeHUh?=
SK-OV-3 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF|LkO3OlMh|ryP M{\EcnNCVkeHUh?=
5637 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF|Lke3OVkh|ryP M2WwdHNCVkeHUh?=
LC-1F MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPqXY5KSzVyPUG0MlA{PTZizszN MY\TRW5ITVJ?
SNB75 NHjN[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF2LkCzPFMh|ryP Mk\FV2FPT0WU
CHP-212 NFHPWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjBTWM2OD1zND6wOFY1KM7:TR?= NEnNTZBUSU6JRWK=
HT-1376 NH\KUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\HZWlEPTB;MUSuNVEzPiEQvF2= M2f2UXNCVkeHUh?=
MONO-MAC-6 NUG1O5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPZN2pXUUN3ME2xOE4yPTB{IN88US=> MYjTRW5ITVJ?
CA46 NIG4c3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj1TWM2OD1zND6xPFI4KM7:TR?= NXvPbmpuW0GQR1XS
SCC-15 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D3PGlEPTB;MUSuOVU5OyEQvF2= M1\XT3NCVkeHUh?=
ATN-1 NELBOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7xSWZKSzVyPUG0MlY3OjdizszN M{fs[XNCVkeHUh?=
NCI-H2405 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF2LkixOVch|ryP MlS2V2FPT0WU
NCI-H716 M1XUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMTWM2OD1zND64OFk{KM7:TR?= NEPBPVZUSU6JRWK=
SW620 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7yW3hKSzVyPUG0MlkxOTRizszN NGG1OFJUSU6JRWK=
NCI-H226 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr0XGpKSzVyPUG0MlkxQDVizszN MYXTRW5ITVJ?
SW962 M3nIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vKXmlEPTB;MUSuPVQ{OiEQvF2= MUTTRW5ITVJ?
KYSE-150 NUnzdYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC3NYdKSzVyPUG0Mlk2PSEQvF2= MofWV2FPT0WU
OCUB-M MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M362WWlEPTB;MUSuPVg5OyEQvF2= NVW2SWhtW0GQR1XS
ES7 NWniUINKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO4epoyUUN3ME2xOU4xQTh2IN88US=> NYjvdGllW0GQR1XS
SW1463 M4XmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:0VXhKSzVyPUG1MlQzOjNizszN MYPTRW5ITVJ?
CAKI-1 NF;kfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jGUmlEPTB;MUWuOVM1PiEQvF2= NHKxbGlUSU6JRWK=
MKN28 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O1[mlEPTB;MUWuOVQ4QSEQvF2= MUjTRW5ITVJ?
SW13 NF[2NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIruW4RKSzVyPUG1MlYyQCEQvF2= MoH3V2FPT0WU
A3-KAW NG[yWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHOTWM2OD1zNT65Olk4KM7:TR?= NInQN4xUSU6JRWK=
LU-65 NU\TdFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTHNFlKSzVyPUG1Mlk4PjhizszN NELUd4FUSU6JRWK=
Calu-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHOTm9KSzVyPUG2MlA{PjhizszN M2rUSnNCVkeHUh?=
ST486 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PHTmlEPTB;MU[uNFQ{OSEQvF2= NHHkd41USU6JRWK=
BB30-HNC MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PT[WlEPTB;MU[uNVI1PiEQvF2= M1vyPHNCVkeHUh?=
EGI-1 M1TReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF4LkS0OkDPxE1? NWLZ[5ZbW0GQR1XS
SH-4 NGnxbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILZXVFKSzVyPUG2MlQ4OzFizszN MlfVV2FPT0WU
MN-60 M{SzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHK[mFKSzVyPUG3MlIzQTdizszN MkDsV2FPT0WU
MPP-89 NX\tRVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;WTWM2OD1zNz6yOFU6KM7:TR?= MXjTRW5ITVJ?
A2780 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\vbFVKSzVyPUG3MlQyOzlizszN MXfTRW5ITVJ?
Daoy M{myTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHMTWM2OD1zNz60Olk2KM7:TR?= NFHGPZpUSU6JRWK=
NCI-H2126 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfBVVZXUUN3ME2xO{41PzdzIN88US=> NX;4bog4W0GQR1XS
NCI-H1563 M1\STGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCyTWM2OD1zNz60PVE4KM7:TR?= M3LOR3NCVkeHUh?=
8-MG-BA NYrKRpU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfPTWM2OD1zNz62OlQ5KM7:TR?= MnjxV2FPT0WU
786-0 NUD4WmxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rnemlEPTB;MUeuPFM2OyEQvF2= NWTUT2ZQW0GQR1XS
AM-38 NH;5bZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DEPGlEPTB;MUeuPVMxPiEQvF2= NH;QTJNUSU6JRWK=
COLO-824 NVPoS20yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\DeWlEPTB;MUiuOFQ{PiEQvF2= MXfTRW5ITVJ?
SK-MEL-30 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF6LkWwPFIh|ryP NHHhO3BUSU6JRWK=
CESS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\DTWM2OD1zOD63OlA6KM7:TR?= MnnnV2FPT0WU
BL-70 M{TYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DGb2lEPTB;MUiuPFE2PiEQvF2= NFnmTJFUSU6JRWK=
NCI-H2170 NFHPZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonaTWM2OD1zOD65NVc6KM7:TR?= MkW5V2FPT0WU
HT-3 M4TZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i0NGlEPTB;MUiuPVg{KM7:TR?= MX7TRW5ITVJ?
BOKU NU\VWpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu2dWpKSzVyPUG5MlA{QDFizszN MWnTRW5ITVJ?
HPAF-II M4XFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTVfYpKSzVyPUG5MlMxOTVizszN M4Py[nNCVkeHUh?=
KGN NFjhWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfIfmxKSzVyPUG5MlQ4PjVizszN M17zNXNCVkeHUh?=
MC-CAR M1nhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPjbphKSzVyPUG5MlY{OTNizszN M4O0UnNCVkeHUh?=
BHT-101 NYHKRYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HQU2lEPTB;MUmuO|c4KM7:TR?= M4DwT3NCVkeHUh?=
SW1783 NXLGeHNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfRUnMxUUN3ME2xPU44QDB4IN88US=> MYrTRW5ITVJ?
KP-N-YN M2nmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;BeYF4UUN3ME2yNE4xOjZ{IN88US=> NGOxXGRUSU6JRWK=
LU-165 NUHMOXNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D4c2lEPTB;MkCuOVU4OSEQvF2= MXPTRW5ITVJ?
GOTO M2ftcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJyLk[0OVEh|ryP M37BUHNCVkeHUh?=
EFM-19 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRTWM2OD1{MT6wO|E3KM7:TR?= M{\odHNCVkeHUh?=
CTV-1 NF24NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDiUXR3UUN3ME2yNU4yODV2IN88US=> M4i4eHNCVkeHUh?=
HEL M3ezXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nhNWlEPTB;MkGuOFIyPiEQvF2= MXLTRW5ITVJ?
SNU-C2B Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPNOGhKSzVyPUKxMlQzPiEQvF2= MontV2FPT0WU
ECC4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHBNYY6UUN3ME2yNU44ODdizszN Mn3vV2FPT0WU
NEC8 NYfiZXFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJzLkizOlgh|ryP MX3TRW5ITVJ?
KMOE-2 M2nlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJzLki5NlEh|ryP MlmzV2FPT0WU
NCI-H524 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrKcVlKSzVyPUKyMlA5ODhizszN MYjTRW5ITVJ?
WSU-NHL Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTWTWM2OD1{Mj6xOVc4KM7:TR?= M3zTT3NCVkeHUh?=
SF126 NIT3dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Hc2lEPTB;MkKuNlQ3QSEQvF2= NHn6NZBUSU6JRWK=
HOP-92 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTjTWM2OD1{Mj6zNVY4KM7:TR?= NILhe|BUSU6JRWK=
CTB-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ{LkS2O|ch|ryP NVPENGxsW0GQR1XS
KYSE-270 M{D3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3NTWM2OD1{Mj65N|U4KM7:TR?= MlvLV2FPT0WU
SK-MEL-24 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\sZm5KSzVyPUKzMlE5PyEQvF2= NHr1WJFUSU6JRWK=
Calu-3 M2mxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X3UWlEPTB;MkOuNlEzQCEQvF2= NEP1c3FUSU6JRWK=
GAMG NXntRmRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu4TWM2OD1{Mz6yN|Y4KM7:TR?= MYXTRW5ITVJ?
SW1573 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TnUWlEPTB;MkOuO|QyPSEQvF2= M2DpPHNCVkeHUh?=
MHH-NB-11 NVLQeG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPQOVVKSzVyPUK0MlAyQTRizszN NUPHbYs{W0GQR1XS
TK10 NWHXT2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n2TmlEPTB;MkSuOVAyOyEQvF2= NXSzPVc{W0GQR1XS
LB373-MEL-D NFvGcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vLNWlEPTB;MkSuOlA3PCEQvF2= NVXwXnJDW0GQR1XS
KALS-1 M3HKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HFbmlEPTB;MkSuO|MzPyEQvF2= NX3ke2x[W0GQR1XS
HUTU-80 NWnQ[ndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ3LkiwN|Ih|ryP M{j1[3NCVkeHUh?=
HuP-T3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjpTWM2OD1{Nj6xOlc1KM7:TR?= NID6NHRUSU6JRWK=
OE19 NFLzUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v3ZWlEPTB;Mk[uNlE2OyEQvF2= MWrTRW5ITVJ?
J82 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jRTmlEPTB;Mk[uNlQ4OSEQvF2= MYXTRW5ITVJ?
DU-4475 NHPCb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF35dVdKSzVyPUK2MlM5OTlizszN M1jWPHNCVkeHUh?=
DMS-53 M3nJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\jSGlEPTB;Mk[uOVE{QCEQvF2= NWrpcmRbW0GQR1XS
COLO-741 NXvMZplWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK5TWM2OD1{Nj64N|Q1KM7:TR?= MWLTRW5ITVJ?
SW48 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCyNFBRUUN3ME2yOk45QDJizszN M2W4bnNCVkeHUh?=
IGR-1 NID0NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHC[XVIUUN3ME2yOk46OzN2IN88US=> MVXTRW5ITVJ?
639-V MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL6XYhKSzVyPUK3MlAzPDVizszN NVH3XHF5W0GQR1XS
LK-2 NIrINWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHJT|ZKSzVyPUK3MlQyPDFizszN MkPBV2FPT0WU
NCI-H2347 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3HTWM2OD1{Nz65Olk6KM7:TR?= M1jMbXNCVkeHUh?=
NCI-H2228 NEHiSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jsRmlEPTB;MkiuNFkxPSEQvF2= MUXTRW5ITVJ?
LS-123 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\nUG9kUUN3ME2yPE4yOjZ{IN88US=> NHLzcINUSU6JRWK=
U031 NH6ze4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ6LkK1NkDPxE1? NXnHe5JIW0GQR1XS
NCI-H1792 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS0TWM2OD1{OD60O|IyKM7:TR?= MXzTRW5ITVJ?
NCI-H2087 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKxTWM2OD1{OD63OVUzKM7:TR?= MYTTRW5ITVJ?
NCI-H2342 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jCbGlEPTB;MkmuOVIxQCEQvF2= M32xN3NCVkeHUh?=
SW626 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXhTWM2OD1{OT63OVYh|ryP NELjXWlUSU6JRWK=
LB2518-MEL MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7oTWM2OD1{OT64NVUh|ryP NYjYO2JpW0GQR1XS
RXF393 NH3UVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPneZR1UUN3ME2zNE4xQTV{IN88US=> MUfTRW5ITVJ?
LC4-1 NH;tZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2THbmlEPTB;M{CuN|A6OiEQvF2= NUTVR|JOW0GQR1XS
NCI-H1694 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HW[mlEPTB;M{CuOlYzPCEQvF2= MUjTRW5ITVJ?
K5 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNyLkm3NFIh|ryP MX3TRW5ITVJ?
HDLM-2 NFvhOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXte2lpUUN3ME2zNE46PzJ3IN88US=> NXfRbJVtW0GQR1XS
BCPAP MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNzLkizO|kh|ryP MofHV2FPT0WU
BC-3 M3vEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTmTWM2OD1|Mj6xOFA{KM7:TR?= MmDUV2FPT0WU
LB996-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nBOGlEPTB;M{KuNlM2QCEQvF2= M2HJ[nNCVkeHUh?=
NCI-H2009 NVPGTYExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXZTWM2OD1|Mj60PVgyKM7:TR?= NW\QdJhmW0GQR1XS
HTC-C3 NYPTS5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC3VWtKSzVyPUOzMlc2OTlizszN MnfmV2FPT0WU
LAMA-84 NX7JRod4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTN2LkS0NFch|ryP NXHMeItiW0GQR1XS
CCRF-CEM MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXOTWM2OD1|ND61O|E2KM7:TR?= Mk\lV2FPT0WU
AN3-CA NUTjOmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN3LkC1Olgh|ryP MXnTRW5ITVJ?
NCI-H1734 NX7ke|dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTN3LkK1OlEh|ryP MXPTRW5ITVJ?
Ca-Ski NELW[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LBXmlEPTB;M{WuOFExOSEQvF2= M1S0eXNCVkeHUh?=
U-266 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HSV2lEPTB;M{WuOlEyPCEQvF2= NH21VFZUSU6JRWK=
SBC-5 NUfwVGV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW5TWM2OD1|NT63O|gyKM7:TR?= MVzTRW5ITVJ?
GT3TKB NIfsToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH3TWM2OD1|Nz6xNVUh|ryP MWLTRW5ITVJ?
MDA-MB-175-VII M2DVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ETWM2OD1|Nz6yNlQ5KM7:TR?= NW\vS3o1W0GQR1XS
PFSK-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTN5LkK0N|Uh|ryP Mm\4V2FPT0WU
IMR-5 M3P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\DTWM2OD1|Nz6yOFg4KM7:TR?= MmPxV2FPT0WU
Daudi M1nw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXI[WZKSzVyPUO3MlM2QTdizszN NWTPZ3ZTW0GQR1XS
A498 M16wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN5LkeyNVgh|ryP M4myVnNCVkeHUh?=
SCC-4 NFj3dnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fiemlEPTB;M{euO|g1OyEQvF2= M4H2PXNCVkeHUh?=
COLO-680N MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LnWWlEPTB;M{iuNlg5PSEQvF2= M3TpenNCVkeHUh?=
SK-MES-1 NGrFTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCxOI5KSzVyPUO4MlMzOTVizszN MWXTRW5ITVJ?
SR MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XxUmlEPTB;M{iuOVQ6PSEQvF2= M2Lz[nNCVkeHUh?=
LNCaP-Clone-FGC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlztTWM2OD1|OD61OlM4KM7:TR?= MlnJV2FPT0WU
SK-HEP-1 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPLVIRbUUN3ME2zPE44QDJ{IN88US=> MXHTRW5ITVJ?
BPH-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fnVWlEPTB;M{iuPFMzQSEQvF2= M2PDWHNCVkeHUh?=
NCI-H1755 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml35TWM2OD1|OT61PFE4KM7:TR?= MlTWV2FPT0WU
LXF-289 NFTBUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTN7LkiwPFQh|ryP MnrvV2FPT0WU
SW1088 NG[4PJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCTWM2OD12MD6yNVA4KM7:TR?= NFXScGFUSU6JRWK=
MOLT-4 NXy4W4dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml32TWM2OD12MD6yPVAyKM7:TR?= MmLPV2FPT0WU
AsPC-1 NYDpTYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PVe2lEPTB;NECuOFU5OyEQvF2= MXHTRW5ITVJ?
HOP-62 NXfvWYF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzTZXRKSzVyPUSwMlY2PjhizszN NVzHcZlNW0GQR1XS
A172 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLuTWM2OD12MD64OVEyKM7:TR?= NX3tUWljW0GQR1XS
SN12C NWDTUWFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRyLkmzPFUh|ryP M3TucHNCVkeHUh?=
MDA-MB-231 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGyOJVUUUN3ME20NE46QDl6IN88US=> NFLDU|RUSU6JRWK=
RPMI-2650 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRzLkG1PVMh|ryP NUXWWmh5W0GQR1XS
KYSE-140 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRzLkixNlMh|ryP NWLTNFRuW0GQR1XS
KINGS-1 NUH4T2UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR{LkS2PVch|ryP NXPO[5hXW0GQR1XS
HSC-3 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHwTWM2OD12Mj62OlYyKM7:TR?= NWLsSZZwW0GQR1XS
PC-14 NX3Qb5FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HVZmlEPTB;NEOuNVg5OiEQvF2= NUG1WWtSW0GQR1XS
COR-L105 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO2TWM2OD12Mz62OVAzKM7:TR?= NIWwUmdUSU6JRWK=
BE-13 NGrYUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\afGlEPTB;NESuNlM4OSEQvF2= NEHMcpJUSU6JRWK=
NCI-H661 NVrHSFBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe4WXFGUUN3ME20OE4zQTV6IN88US=> MkjHV2FPT0WU
IST-MEL1 M4fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR2LkO1PVkh|ryP NXzGbIVuW0GQR1XS
HCC1806 M3zufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnLUII3UUN3ME20OE42QDd|IN88US=> NV3qOXd{W0GQR1XS
COLO-800 M4rnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnGTWM2OD12ND64OFU{KM7:TR?= MUDTRW5ITVJ?
IST-SL2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vR|NbUUN3ME20OU4yOjR5IN88US=> MmD6V2FPT0WU
8305C NUfIR4plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjWd2tKSzVyPUS1MlMxQSEQvF2= NYnJVoFkW0GQR1XS
UACC-62 NFu5S5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7uTWM2OD12Nj6yPFc2KM7:TR?= MnftV2FPT0WU
COR-L23 NGTHb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m3emlEPTB;NEeuNVk6KM7:TR?= NGPqdWdUSU6JRWK=
EFE-184 NXO2NGxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP2R4ZKSzVyPUS3MlM5QCEQvF2= Mle1V2FPT0WU
DMS-114 NWDPWIRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTPTnZKSzVyPUS3MlQyPDlizszN NHHSZ2lUSU6JRWK=
KYSE-520 NIDLblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPsTIxKSzVyPUS4MlU{OTVizszN NITnbmJUSU6JRWK=
SNG-M MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXITWM2OD12OT60N|Qh|ryP MoXtV2FPT0WU
A2058 NGq4dXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF61VotKSzVyPUS5MlQ5QDVizszN MYrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
臨床試験 OSI-906 is currently under a Phase III clinical trial in adrenocortical carcinoma (ACC).
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

細胞アッセイ: [1]

細胞株 MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
濃度 0.02-0.8 μM
反応時間 3 days
実験の流れ For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

動物実験: [1]

動物モデル IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
製剤 25 mM tartaric acid
投薬量 25 mg / kg and 75 mg / kg
投与方法 Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download OSI-906 (Linsitinib) SDF
分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

文献中の引用 (15)

Frequently Asked Questions

  • Question 1
    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

    Answer: OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related IGF-1R 阻害剤

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP)は一種の選択性的なIGF-1R阻害剤で、IC50値が1 nMです。臨床 1/2です。

  • Erlotinib

    Erlotinibは一種のEGFR阻害剤で、このIC50値が2 nMです。Erlotinibは、EGFRに対する敏感性は人間c-Src或いはv-Abに対する敏感性より1000倍以上が高くなります。

  • R428 (BGB324)

    R428 (BGB324)は一種のAxl阻害剤で、IC50値が14 nMです。R428 (BGB324)は、Axlに作用する選択性はAblに作用する選択性より100倍以上が高くなって、MerとTyro3に作用する選択性より50倍-100倍が高くなって、InsR、EGFR、HER2とPDGFRβに作用する選択性より100倍余りが高くなります。

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397)は一種の経口有効な多ターゲットCSF-1R、KitとFlt3受容体チロシンキナーゼ阻害剤で、IC50値が20 nM、10 nMと160 nMにそれぞれ分かれることです。臨床3期。

  • BMS-536924

    BMS-536924は一種のATP競争性的なIGF-1R/IR阻害剤で、このIC50値が100 nM/73 nMです。BMS-536924はMek、FakとLckに適合な抑制活性を表しますが、Akt1とMAPK1/2に抑制活性を殆ど表しません。

  • NVP-AEW541

    NVP-AEW541は一種の有効なIGF-1R/InsR阻害剤で、無細胞実験でこのIC50値が150 nM/140 nMです。NVP-AEW541は無細胞実験の中に、IGF-1Rにもっと高い作用と選択性を表します。

  • NVP-ADW742

    NVP-ADW742は一種のIGF-1R阻害剤で、このIC50値が0.17μMです。NVP-ADW742は、IGF-1Rに作用する効果はInsRに作用する効果より16倍以上が高くなりますが、HER2、PDGFR、VEGFR-2、Bcr-Ablとc-Kitに活性を殆ど表しません。

  • GSK1904529A

    GSK1904529Aは一種の選択性的なIGF-1RとIRの阻害剤で、無細胞実験でこのIC50値が27 nMと25 nMです。GSK1904529Aは、IGF-1R/InsRに作用する選択性はAkt1/2、Aurora A/B、B-Raf、CDK2、EGFR等に作用する選択性より100倍以上が高くなります。

  • BMS-754807

    BMS-754807は一種の有効で、可逆的なIGF-1R/InsR阻害剤で、無細胞実験でIC50値が1.8 nM/1.7 nMです。BMS-754807はMet、Aurora A/B、TrkA/BとRonに作用する効果が少し弱くて、Flt3、Lck、MK2、PKAとPKC等を抑制する活性がありません。臨床2期。

    Features:Muti-inhibitor of the IGR-1R/IR family.

最近チェックしたアイテム

Tags: OSI-906 (Linsitinib)を買う | OSI-906 (Linsitinib)供給者 | OSI-906 (Linsitinib)を購入する | OSI-906 (Linsitinib)費用 | OSI-906 (Linsitinib)生産者 | オーダーOSI-906 (Linsitinib) | OSI-906 (Linsitinib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ